Invox Pharma Limited

F-star Therapeutics, Inc.

Francisca Wollerton

Mihriban Tuna

Jose Munoz-Olaya

Matthew Lakins

Neil Brewis

Remi Fertin

Sachin Badrinath Surade

Michael Dyson

Claire Reader

Alexander Koers

Sarah Batey

Mateusz Wydro

The present application relates to antibody molecules that bind both PD-L1 and CD 137 and are able to induce agonism of CD137. The antibody molecules comprise a CDR-based binding site for PD-L1, and a CD137 antigen-binding site that is located in a constant domain of the antibody molecule. The antibody molecules of the invention find application, for example, in the treatment of diseases, such as cancer.

Antibody molecules that bind PD-L1 and CD137

The present application relates to antibody molecules that bind mesothelin (MSLN). The antibody molecules find application in the treatment and diagnosis of diseases and disorders, such as cancer.

Anti-mesothelin antibodies

The present invention relates to antibody molecules that bind both mesothelin (MSLN) and CD137. The antibody molecules comprise a CDR-based binding site for MSLN, and a CD137 antigen-binding site located in a constant domain of the antibody molecule. The antibody molecules find application in the treatment of cancer, for example.

Mesothelin and CD137 binding molecules

The present disclosure, in some aspects, provides antibody molecules, or antigen-binding fragments thereof capable of binding specifically to PD-L1. The present disclosure further provides antibody molecules, or antigen-binding fragments thereof capable of binding specifically to PD-L1 and a second antigen-binding site. Methods of making and/or using such antibody molecules or antigen bending fragments are also provided.

Antibody molecules

Growing community of inventors

Cambridge, United Kingdom

Francisca Wollerton